New Hope on the Horizon - Advances in the Diagnosis and Treatment of Idiopathic Hypersomnia
Idiopathic hypersomnia (IH) is a chronic neurological disorder that has significant impacts on daily functioning, with symptoms that include, but often go beyond excessive daytime sleepiness (EDS). Overall awareness about IH remains low, which contributes to the suboptimal recognition of this condition, which is often exacerbated by insufficient diagnostic criteria leading to delayed diagnosis and treatment. Until recently, there was no FDA approved treatment option for IH, and historically, although IH is not the same as narcolepsy, the same treatment options were offered, leading to suboptimal treatment response and exacerbation of disease burden. Recent advances, with a new option now approved and other agents in development, can help close some of the current gaps.
In this activity, experts will offer expert perspectives on the impact of IH, as well as best practices and advances for its screening, diagnosis, and treatment. The information is presented in an easy and digestible format, accompanied by additional resources and suggested readings.
US-based healthcare professionals, including cardiologists, endocrinologists, lipidologists, primary care clinicians (PCPs), sleep specialists, registered nurses, advanced practice registered nurses, dieticians, pharmacists, and other allied health professionals involved in the management and treatment of cardiometabolic patients.
After completing this activity, the participant should be better able to:
- Review the pathophysiology, definitions, and the burden of idiopathic hypersomnia (IH) on patients’ quality of life.
- Summarize the clinical features and the current and emerging diagnostic parameters for IH.
- Discuss the burden of IH and practical approaches to assess the severity of IH symptoms.
- Describe conventional treatment options for IH and challenges with current treatments.
- Outline the rationale, efficacy and safety of new and emerging therapies for the treatment of IH.
Michael J. Thorpy, MD
Professor of Neurology
Albert Einstein College of Medicine Director, Sleep-Wake Disorders Center
Department of Neurology
Montefiore Medical Center
Dr. Thorpy discloses the following:
• Consultant/Advisory Board: Axsome, Balan
Yves Dauvilliers, MD, PhD
Professor of Neurology and Physiology
University of Montpellier
Director, Sleep-Wake Disorders Centre
Department of Neurology
Gui de Chauliac Hospital
Dr. Dauvilliers discloses the following:
• Consultant: JAZZ, Takeda, orexia, Avadel, Idorsia
ESTIMATED TIME TO COMPLETE ACTIVITY
EDUCATIONAL GRANT SUPPORT
Supported by an educational grant from Jazz Pharmaceuticals, Inc.
JOINT PROVIDERSHIP STATEMENT
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Cardiometabolic Health Congress (CMHC). PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CONTINUING EDUCATION
PACE designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NURSING CONTINUING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.75 contact hours. Pharmacotherapy contact hours for Advance Practice Registered Nurses will be designated on your certificate.
PHARMACY CONTINUING EDUCATION
PACE designates this continuing education activity for 1.75 contact hour(s) (0.175 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - JA4008073-9999-23-225-H01-P Type of activity: Application
For Pharmacists: Upon completing the post-test and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 – 6 weeks.
METHOD OF PARTICIPATION & REQUEST FOR CREDIT
There are no registration fees for this activity. During the period November 9, 2023 through November 9, 2024, participants must read the learning objectives and faculty disclosures, study the educational activity, obtain a score of 75% or better on the post-test, and complete the evaluation. Upon completing, your certificate will be available for print. For questions about receiving certificates, please contact us at CMHC_Eval@cardiometabolichealth.org.
For additional information about the accreditation of this activity, please visit https://partnersed.com
For Pharmacists: Please complete the evaluation instructions above. Upon registering and completing the activity evaluation, your transcript information will be sent to the NABP CPE Monitor Service within 4-6 weeks.
The PACE planners and others have no relevant financial relationship(s) to disclose with ineligible companies. The CMHC planners and others have no relevant financial relationship(s) to disclose with ineligible companies.
DISCLOSURE OF CONFLICT OF INTEREST
PACE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial relationships they may have with ineligible companies. All relevant financial relationships are thoroughly vetted and mitigated according to PACE policy. PACE is committed to providing learners with high-quality accredited CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
- 1.75 ACPE Pharmacy
- 1.75 AMA PRA Category 1 Credit™
- 1.75 ANCC
- 1.75 Participation
A computer with an internet connection
Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.